Bessemer Group
MAZE

Bessemer Group’s Maze Therapeutics MAZE Stock Holding History

Bessemer Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Hold
481,790
– – 0.02% 346
2026
Q1 		$14.4M Hold
481,790
– – 0.02% 312
2025
Q4 		$20M Hold
481,790
– – 0.03% 281
2025
Q3 		$12.5M Hold
481,790
– – 0.02% 298
2025
Q2 		$5.91M Hold
481,790
– – 0.01% 342
2025
Q1 		$5.3M Buy
+481,790
New +$5.8M 0.01% 346

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Bessemer Group's MAZE Position: Q2 2026 in Review

Bessemer Group held its Maze Therapeutics (MAZE) position steady in Q2 2026 at 481,790 shares worth $14.4M. The position accounts for 0.02% of the portfolio, ranked #346.

Bessemer Group first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $20M in Q4 2025. 161 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Bessemer Group held 481,790 shares of Maze Therapeutics worth $14.4M as of Q2 2026.
  • Bessemer Group left its Maze Therapeutics share count unchanged in Q2 2026.
  • Maze Therapeutics made up 0.02% of Bessemer Group's portfolio in Q2 2026, its #346 holding.
  • Bessemer Group first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Bessemer Group's Maze Therapeutics position peaked at $20M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.